BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Bristol-Myers Squibb Company (BMY) Transfers $1.4 Billion Of Risk To Prudential 10/1/2014 6:25:21 AM
Gilead Sciences, Inc. (GILD) Looks To Erase Bristol-Myers Squibb Company (BMY)'s Early Hep C Lead 9/30/2014 7:05:34 AM
Bristol-Myers Squibb Company (BMY) Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor 9/29/2014 11:55:22 AM
Bristol-Myers Squibb Company (BMY) Release: European Medicines Agency Validates The Marketing Authorization Application For Nivolumab In Non-Small Cell Lung Cancer 9/29/2014 11:41:00 AM
Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Charitable Donations Of More Than $1 Million To Support Cardiovascular Education For Patients And Caregivers 9/22/2014 10:39:51 AM
Bristol-Myers Squibb Company (BMY) Takes Immunotherapy Rivalry With Merck & Co. (MRK) To The Courts 9/8/2014 5:49:28 AM
Bristol-Myers Squibb Company (BMY) Release: Secondary Analysis Of AMPLIFY-EXT Examining Predictors Of Hospitalization Presented At ESC Congress: Eliquis (Apixaban) Significantly Reduced The Risk Of All-Cause Hospitalization Versus Placebo In Patients With Venous Thromboembolism (VTE) 9/2/2014 1:24:03 PM
Bristol-Myers Squibb Company (BMY) To Take Part In Morgan Stanley (MST) Global Health Care Conference 9/2/2014 10:56:14 AM
Bristol-Myers Squibb Company (BMY) Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab 9/2/2014 8:12:26 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Present New Data On Eliquis® (Apixaban) At The European Society of Cardiology Congress 2014 8/20/2014 8:41:27 AM
12345678910...